Coronavirus vaccine: another successful study
Ten post jest także dostępny w języku: polski
Are we approaching a breakthrough in the development of a vaccine for the coronavirus causing COVID-19 disease? Another company informed about the results of the first phase of clinical trials. The vaccine developed by the biotechnological company Moderna Therapeutics is causing an immunological response. However, it will be subjected to further testing.
COVID-19 vaccine – global offensive in progress
The Moderna’s vaccine against COVID-19 was the first to start tests on humans. It was 66 days after the release of the virus’s genetic sequence. It is worth noting that Moderna Therapeutics has already been involved in the development of a vaccine for MERS-CoV, another type of coronavirus. At that time, however, the program ended at the research stage and there were no clinical trials on humans. The development of a vaccine for COVID-19 in such a record time was possible thanks to the use of mRNA technology. It works with the virus sequence, not with the virus itself.
As the COVID-19 coronavirus continues to progress, the vaccine seems to be a breakthrough in coping with the pandemic. Currently, 13.4 million people worldwide have received positive results for the presence of Sars-CoV-2 coronavirus, 580 thousand of whom died. As we wrote recently, many companies are currently working on developing a vaccine for coronavirus. Recently, Pfizer and BioNTech published the results of their research.
Results of coronavirus vaccine tests and market entry
The Phase 1 analysis of Moderna’s vaccine assessed the schedule of mRNA-1273 vaccination in the efficacy of antibody production to build resistance to COVID-19 coronavirus. The vaccine was tested on 45 healthy adults aged 18-55 years. Patients received two vaccinations at an interval of 28 days at a dose of 25μg, 100μg or 250μg. There were 15 participants in each dose group. mRNA-1273 induced immune responses against SARS-CoV-2 in all subjects and no safety concerns were identified.
According to Moderna, the sustainability of the immune response of the vaccine to COVID-19 coronavirus is currently under evaluation. Phase 1 subjects will be monitored for another year after the second vaccination. It should be noted that the vaccine also caused adverse events that occurred in more than half of the subjects. However, these effects were generally transient and mild to moderate.